Home Ingredients Rye Grass Pollen Extract (Flower Pollen Extract)
Prostate HealthKidney/Urinary TractMen's Health

Rye Grass Pollen Extract (Flower Pollen Extract)

Secale cereale
Evidence Level
Limited
7 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Rye grass pollen extract is a standardized extract of flower pollen from rye (Secale cereale), sold mainly as Cernilton, made from cernitin extract, and as Graminex, a blend of rye, corn and timothy pollen extracts. It is not bee pollen, which is gathered by bees and eaten whole. It has been studied in older men with urinary symptoms from benign prostate enlargement and in men with chronic pelvic pain thought to come from the prostate. A Cochrane review of four small, short trials found that more men rated their urinary symptoms and nighttime urination as improved, but urine flow and prostate size did not change; that review was later withdrawn because it was not being updated. In pelvic pain, a 139-man placebo-controlled trial was positive, while pooled analyses disagree. Side effects in trials were rare and mild. New urinary symptoms or pelvic pain need a medical check before self-care.

Studied Dose Most trials used 2 capsules or tablets three times a day for 8 weeks to 6 months. In two Japanese trials each unit held 63 mg of cernitin extract (about 378 mg/day); the European capsule lists 23 mg dry pollen extract. A 4-year Chinese study used 375 or 750 mg twice daily.
Active Compound Standardized rye grass (Secale cereale) pollen extract. Cernilton combines two cernitin fractions (T60 and GBX); Graminex blends extracts of rye, corn (Zea mays) and timothy (Phleum pratense) pollen.

Benefits

Prostate support: urinary symptoms and nighttime urination in older men

A Cochrane review of 4 controlled trials in 444 men with benign prostate enlargement, lasting 12 to 24 weeks, found that more men on rye pollen extract rated their urinary symptoms as improved than on placebo (risk ratio 2.40) and that nighttime urination improved more. The trials were small and short, and how treatment was allocated was unclear in all of them. The review was later withdrawn because it was not being updated.

Supported by Trial 1

Pelvic discomfort and prostate symptom scores in men

In a 12-week placebo-controlled trial in 139 men with chronic pelvic pain and signs of prostate inflammation, the extract improved pain, quality of life and total symptom scores; 70.6% responded versus 50.0% on placebo. A pooled analysis of 4 trials, 2 of them without a placebo group, was positive, but a newer one that mixed pollen with other products found no clear benefit.

Supported by Trial 3, Trial 6

Urine flow, residual urine and prostate size

Objective measures are where the evidence is weakest. Pooled across controlled trials, the extract did not improve urine flow rate, urine left in the bladder or prostate size compared with placebo or other products. In one 60-man placebo trial, residual urine and prostate diameter fell on the extract, but flow rate did not differ from placebo.

Supported by Trial 1, Trial 2

Longer-term use over months to years

Most controlled trials lasted 6 months or less. In a 4-year Chinese study of 240 men, the higher of two doses gave larger symptom and flow gains and fewer cases of urinary retention and surgery than the lower dose, but there was no placebo group. An uncontrolled Japanese study of 79 men reported better symptoms and flow and no side effects.

Supported by Trial 1, Trial 7

Use alongside prescribed prostate medicines

In men whose pelvic pain persisted on an alpha-blocker, adding the extract for 12 weeks lowered pain scores in a trial without a placebo group. In men with urinary symptoms, the alpha-blocker tamsulosin, alone or combined with the extract, worked better than the extract alone. Neither trial supports replacing a prescribed medicine.

Supported by Trial 7, Trial 5

Mechanism of action

1

Prostate tissue and cell growth in lab and animal studies

In older rats with hormone-induced prostate inflammation, the full extract reduced damage to the gland lining and limited overgrowth of the supporting tissue, with each of its two fractions accounting for one of these effects. In prostate cell lines, both fractions slowed cell growth and lowered androgen receptor and PSA protein in stromal cells. These are lab and animal findings, and two of the cell study's authors worked for the maker.

2

Inflammatory signals in immune and prostate cells

In immune cells and prostate cell lines, the extract raised the anti-inflammatory messenger IL-10, but it also raised the pro-inflammatory messengers IL-6 and IL-8. How these test-tube effects relate to pelvic pain or urinary symptoms in men is not known.

Clinical trials

1
Cochrane Review of Cernilton in Men With Prostate Enlargement: Self-Rated Symptoms Better, Flow Unchanged
PubMed

Cochrane systematic review of randomized or controlled trials comparing Cernilton with placebo or other products in men with benign prostatic hyperplasia; the 2011 reissue was withdrawn because the authors were not going to update it (Wilt et al. 2000, Cochrane Database Syst Rev)

444 men in 2 placebo-controlled and 2 comparative trials lasting 12 to 24 weeks.

More men reported satisfactory or improved urinary symptoms on Cernilton than on placebo (risk ratio 2.40, 95% CI 1.21 to 4.75), and nighttime urination improved (risk ratio 2.05 versus placebo). Urine flow, residual urine and prostate size did not improve. Withdrawal rates were 4.8% on Cernilton and 2.7% on placebo. The authors called the trials short and small with unclear allocation concealment and unknown preparation quality, and the comparison products were not proven treatments.

2
Cernilton vs Placebo for 6 Months in 60 Men With Urinary Outflow Obstruction
PubMed

Double-blind, placebo-controlled trial of a 6-month course of Cernilton in men with outflow obstruction due to benign prostatic hyperplasia (Buck et al. 1990, Br J Urol)

60 men with outflow obstruction due to benign prostatic hyperplasia.

69% of men on Cernilton reported subjective improvement versus 30% on placebo, a significant difference. Residual urine and the front-to-back diameter of the prostate on ultrasound fell significantly with Cernilton, but flow rate and voided volume did not differ significantly from placebo.

3
Cernilton vs Placebo for 12 Weeks in 139 Men With Chronic Pelvic Pain: Phase 3 RCT
PubMed

Multicentre, randomised, double-blind, placebo-controlled phase 3 trial led by the University of Giessen, Germany; 2 capsules every 8 hours for 12 weeks. The registry entry (NCT00919893) lists Cernelle (Sweden) and Strathmann (Germany) as collaborators (Wagenlehner et al. 2009, Eur Urol)

139 men with inflammatory chronic prostatitis/chronic pelvic pain syndrome (NIH category IIIA); 70 on pollen extract, 69 on placebo.

The primary outcome, the pain domain of the NIH Chronic Prostatitis Symptom Index, improved more than on placebo (p = 0.0086), as did quality of life and the total score. 70.6% of men on the extract responded (a drop of at least 25% or 6 points) versus 50.0% on placebo. Adverse events were minor.

4
Grass Pollen Extract Prostat/Poltit vs Placebo for 6 Months in 60 Men With Chronic Pelvic Pain
PubMed

Randomized, double-blind, placebo-controlled trial, published by a single author, of Prostat/Poltit, an extract of pollen from selected grass species, for 6 months (Elist 2006, Urology)

60 men aged 20 to 55 with chronic nonbacterial prostatitis/chronic pelvic pain syndrome who had not responded to earlier treatment for more than 6 months.

More men on the extract were rated cured or improved than on placebo, and no adverse reactions were found. The abstract gives no figures; a later review tabulated response as 73.3% of 30 men versus 64.2% of 28 on placebo. Prostat/Poltit is a different grass pollen product from Cernilton.

5
Cernitin vs Tadalafil Added to an Alpha-Blocker in 100 Men With Persistent Pelvic Pain (No Placebo)
PubMed

Randomized trial in Japan comparing add-on cernitin pollen extract (4 capsules a day) with add-on tadalafil 5 mg/day for 12 weeks in men still in pain on an alpha-blocker (Matsukawa et al. 2020, Neurourol Urodyn)

100 men with chronic prostatitis/chronic pelvic pain syndrome and urinary symptoms despite alpha-blocker therapy; 42 and 45 included in the final analysis.

Both groups improved. Total symptom index scores fell by 6.8 points with cernitin and 4.6 with tadalafil (P = .02), and pain scores by 4.1 and 1.5 (P < .001). Urinary symptom scores improved significantly more with tadalafil. There was no placebo group.

6
Cernilton vs Eviprostat for 8 Weeks in 100 Men With Chronic Pelvic Pain (No Placebo)
PubMed

Randomized trial in Japan comparing Cernilton (2 capsules every 8 hours, each with 60 mg cernitin T60 and 3 mg cernitin GBX) with the herbal product Eviprostat for 8 weeks (Iwamura et al. 2015, BMC Urol)

100 men with category III chronic prostatitis/chronic pelvic pain syndrome, 50 per group.

Response, defined as at least a 25% drop in the total symptom index, was 78.1% with the pollen extract and 88.2% with Eviprostat, with no significant difference in total, pain, urinary or quality of life scores. No severe adverse events occurred. With no placebo arm, the trial cannot show how much either product helped beyond placebo, and the authors called the samples very small.

7
Tamsulosin, Cernitin or Both for 12 Weeks in 243 Men With Urinary Symptoms
PubMed

Multicentre randomized trial in Japan, published in Japanese, of tamsulosin, cernitin pollen extract or the combination for 12 weeks (Aoki et al. 2002, Hinyokika Kiyo)

243 men with urinary symptoms associated with benign prostatic hyperplasia.

Prostate symptom scores improved in all three groups, but peak and average urine flow rose significantly only in the groups given tamsulosin. The authors concluded that tamsulosin alone or combined was more effective than cernitin alone. There was no placebo group.

Side effects and drug interactions

Common Potential side effects

Side effects in trials were rare and mild; in the Cochrane review 4.8% of men stopped Cernilton early versus 2.7% on placebo.
Trials in men with pelvic pain reported only minor adverse events, and a 4-year study at two doses reported none, but few trials lasted longer than 6 months.
The extract is made from grass pollen. People with grass pollen allergy were not studied separately, so check with a doctor or allergist before trying it.
It has been studied almost entirely in men; it has not been tested in pregnancy or breastfeeding.
Urinary symptoms, pelvic pain and a weak stream can have causes such as infection or prostate cancer. See a doctor before self-treating, and do not use this in place of prescribed care.

Important Drug interactions

PSA tests: in an uncontrolled study of 61 men, 30 days of cernitin pollen extract lowered PSA by an average of 0.6 ng/mL (7.6%). Tell your doctor you take it before a PSA test.
Alpha-blockers such as tamsulosin: the extract was given alongside them in two trials, which were not designed to study interactions. Tell your prescriber if you take one.
Finasteride, dutasteride and other prostate medicines: combined use has not been studied. Do not stop or replace a prescribed medicine without medical advice.
No formal drug interaction studies of rye grass pollen extract have been published.

More Prostate Health Ingredients

Prostate Health
Plasys300® (Rye Pollen and Beta-Sitosterol Blend — Pharmactive)
Plasys300 is an ingredient from Pharmactive Biotech Products that combines cereal pollen (…
Cardiovascular
Beta-Sitosterol
Beta-sitosterol is one of the main plant sterols in the diet, a cholesterol-like compound…
Hair, Skin & Nails
Saw Palmetto
Saw palmetto (Serenoa repens) is a small palm whose berry extract is one of the most widel…
Kidney/Urinary Tract
Pygeum (African Plum / Prunus Africana)
Pygeum is a bark extract from the African plum tree (Prunus africana). It has been studied…

Explore Other Ingredients

Anti-Inflammatory
Bromelain
Bromelain is a group of protein-digesting enzymes from the pineapple stem. Its most consis…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids are polyunsaturated fats. EPA and DHA come from fish, krill and algae…
Antioxidant
Curcumin/Turmeric
Curcumin, the main bioactive compound in turmeric (Curcuma longa), is usually taken as a s…

Frequently asked questions about Rye Grass Pollen Extract (Flower Pollen Extract)

Is rye grass pollen extract the same as bee pollen?

No. Rye grass pollen extract is a standardized extract made from pollen of rye and, in some products, other grasses, and it is sold in measured capsule doses. Bee pollen is pollen gathered and packed by honeybees and eaten whole. The prostate and pelvic pain trials on this page tested pollen extracts, not bee pollen.

What is the difference between Cernilton and Graminex?

Cernilton is made from cernitin, a rye grass pollen extract with two fractions, and it is the product used in most of the trials on this page, including the Cochrane review and the 139-man pelvic pain trial. Graminex is a blend of rye, corn and timothy pollen extracts, and in pelvic pain trials it was mostly tested together with B vitamins. The two are not interchangeable, and results for one do not automatically apply to the other.

Does it shrink the prostate or improve urine flow?

Not on the pooled evidence. In the Cochrane review, the extract did not improve urine flow, urine left in the bladder or prostate size compared with placebo. Its benefits in controlled trials were in how men rated their symptoms and in nighttime urination. One small trial did report a fall in residual urine on the extract, without a change in flow.

How long does it take to notice a difference?

Trials measured results after 8 weeks to 6 months, most often at 12 weeks, so a fair trial is about 3 months. If symptoms worsen, or you notice blood in the urine, fever or trouble passing urine, see a doctor promptly.

Can it affect a PSA test?

It may. In one uncontrolled study, 30 days of cernitin pollen extract lowered PSA by about 7.6% on average. Tell your doctor you take it before a PSA test so the result can be read correctly.

What is Rye Grass Pollen Extract?

Rye grass pollen extract is a standardized extract of flower pollen from rye (Secale cereale), sold mainly as Cernilton, made from cernitin extract, and as Graminex, a blend of rye, corn and timothy pollen extracts. It is not bee pollen, which is gathered by bees and eaten whole.

What is Rye Grass Pollen Extract used for?

Rye Grass Pollen Extract is researched primarily for Prostate Health, Kidney/Urinary Tract, and Men's Health. A Cochrane review of 4 controlled trials in 444 men with benign prostate enlargement, lasting 12 to 24 weeks, found that more men on rye pollen extract rated their urinary symptoms as improved than on placebo (risk ratio 2.

What is the recommended dosage of Rye Grass Pollen Extract?

The clinically studied dose is Most trials used 2 capsules or tablets three times a day for 8 weeks to 6 months. In two Japanese trials each unit held 63 mg of cernitin extract (about 378 mg/day); the European capsule lists 23 mg dry pollen extract. Always follow the product label and check with a healthcare provider for personal advice.

Is Rye Grass Pollen Extract safe, and does it have side effects?

For most healthy adults, Rye Grass Pollen Extract is well tolerated at studied doses. Reported effects can include: Side effects in trials were rare and mild; in the Cochrane review 4.8% of men stopped Cernilton early versus 2.7% on placebo. Trials in men with pelvic pain reported only minor adverse events, and a 4-year study at two doses reported none, but few trials lasted longer than 6 mont… It may also interact with some medications. Rye Grass Pollen Extract is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Rye Grass Pollen Extract interact with any medications?

Possible interactions include: PSA tests: in an uncontrolled study of 61 men, 30 days of cernitin pollen extract lowered PSA by an average of 0.6 ng/mL (7.6%). Tell your doctor you take it before a PSA test. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Rye Grass Pollen Extract?

NutraSmarts rates the evidence for Rye Grass Pollen Extract as Limited (2 out of 5). It is backed by 7 clinical trials and 16 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(16 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001042. doi: 10.1002/14651858.CD001042.PubMedUsed to support: Cochrane review of Cernilton, made from rye grass pollen, in men with benign prostatic hyperplasia: 444 men in 2 placebo-controlled and 2 comparative trials lasting 12 to 24 weeks. More men rated their urinary symptoms as improved than on placebo (risk ratio 2.40) and nighttime urination improved (risk ratio 2.05), but urine flow, residual urine and prostate size did not. Adverse events were rare and mild. The authors judged the trials short, small and of unclear allocation concealment, with unknown preparation quality.
  2. Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. WITHDRAWN: Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2011;2011(5):CD001042. doi: 10.1002/14651858.CD001042.pub2.PubMedUsed to support: The 2011 reissue of the Cochrane Cernilton review, with the same results as the 2000 version. It was withdrawn from publication because the authors indicated they would not update it, not because its findings were found to be wrong. No newer Cochrane review of Cernilton has replaced it.
  3. Buck AC, Cox R, Rees RW, Ebeling L, John A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. Br J Urol. 1990;66(4):398-404. doi: 10.1111/j.1464-410x.1990.tb14962.x.PubMedUsed to support: Double-blind placebo-controlled 6-month trial in 60 men with outflow obstruction from prostate enlargement. 69% reported subjective improvement on Cernilton versus 30% on placebo; residual urine and prostate diameter fell, but flow rate and voided volume did not differ significantly.
  4. Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brähler E, Weidner W. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544-51. doi: 10.1016/j.eururo.2009.05.046.PubMedUsed to support: Phase 3 placebo-controlled trial in 139 men with inflammatory chronic pelvic pain syndrome given 2 capsules every 8 hours for 12 weeks. Pain, quality of life and total NIH Chronic Prostatitis Symptom Index scores improved more than on placebo, with 70.6% versus 50.0% responding. Adverse events were minor.
  5. Elist J. Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study. Urology. 2006;67(1):60-3. doi: 10.1016/j.urology.2005.07.035.PubMedUsed to support: Double-blind placebo-controlled 6-month trial in 60 men aged 20 to 55 with long-standing chronic pelvic pain. More men on the grass pollen extract Prostat/Poltit were rated cured or improved than on placebo, and no adverse reactions were found. The abstract reports no numbers, and the study had a single author.
  6. Cai T, Verze P, La Rocca R, Anceschi U, De Nunzio C, Mirone V. The role of flower pollen extract in managing patients affected by chronic prostatitis/chronic pelvic pain syndrome: a comprehensive analysis of all published clinical trials. BMC Urol. 2017;17(1):32. doi: 10.1186/s12894-017-0223-5.PubMedUsed to support: Review of pollen extract studies in chronic pelvic pain syndrome: 6 uncontrolled studies (206 men) and 4 randomized trials (384 men). The pooled analysis favored pollen extract (odds ratio 0.52), but 2 of the 4 trials compared it with ibuprofen or another herbal product rather than placebo, and the ibuprofen trial, by the review's lead author, tested pollen extract combined with B vitamins. The full text describes Graminex as a blend of rye, corn and timothy pollen extracts, and records that Prostat/Poltit contains 74 mg of grass pollen extract. Three authors disclosed consulting for and research support from IDIpharma.
  7. Alshahrani S, Fathi BA, Abouelgreed TA, El-Metwally A. Comparative Efficacy of Pharmacological Interventions for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Healthcare (Basel). 2025;13(22):2956. doi: 10.3390/healthcare13222956.PubMedUsed to support: Meta-analysis of drug and plant treatments for chronic pelvic pain syndrome. Its pollen extract group (9 studies) showed no significant benefit (mean difference minus 2.56 points, 95% CI minus 10.83 to 5.71) with very low certainty and 99% heterogeneity. The full text shows that group also included trials of quercetin, cranberry juice and curcumin and calendula suppositories, so it is not a clean test of pollen extract.
  8. Matsukawa Y, Naito Y, Funahashi Y, Ishida S, Fujita T, Tochigi K, Kato M, Gotoh M. Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study. Neurourol Urodyn. 2020;39(7):1994-2002. doi: 10.1002/nau.24454.PubMedUsed to support: Randomized trial in 100 men with pelvic pain that persisted on an alpha-blocker, given add-on cernitin (4 capsules a day) or tadalafil 5 mg/day for 12 weeks. Both groups improved; total and pain scores fell more with cernitin, while urinary symptoms improved more with tadalafil. There was no placebo group.
  9. Iwamura H, Koie T, Soma O, Matsumoto T, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Ohyama C. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urol. 2015;15:120. doi: 10.1186/s12894-015-0115-5.PubMedUsed to support: Randomized 8-week trial in 100 men with chronic pelvic pain syndrome comparing Cernilton (each capsule 60 mg cernitin T60 plus 3 mg cernitin GBX, 2 capsules every 8 hours) with Eviprostat. Response rates were 78.1% and 88.2%, with no significant difference, and no severe adverse events. No placebo group.
  10. Aoki A, Naito K, Hashimoto O, Yamaguchi M, Hara Y, Baba Y, Wada T, Joko K, Nagao K, Yamakawa G, Suyama K, Nagata K, Matsuyama H, Hirao H, Shimizu Y, Hironaka H, Isoyama R, Takemoto M, Tuchida M, Shiraishi K, Kato M, Kamiryo Y, Harada H, Otsuka T, Mitsui H, Nasu T, Hayashida S, Jojima K, Sacho T, Koshido Y, Harada N. [Clinical evaluation of the effect of tamsulosin hydrochloride and cernitin pollen extract on urinary disturbance associated with benign prostatic hyperplasia in a multicentered study]. Hinyokika Kiyo. 2002;48(5):259-67.PubMedUsed to support: Japanese-language randomized trial in 243 men with urinary symptoms from prostate enlargement given tamsulosin, cernitin pollen extract or both for 12 weeks. Symptom scores improved in all groups, but urine flow rose significantly only with tamsulosin, and tamsulosin alone or combined was judged more effective than cernitin alone.
  11. Xu J, Qian WQ, Song JD. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia]. Zhonghua Nan Ke Xue. 2008;14(6):533-7.PubMedUsed to support: Chinese-language 4-year study in 240 men with prostate enlargement given Cernilton at 750 mg or 375 mg twice daily, with no placebo group. The higher dose gave larger improvements in symptoms, flow and residual urine and fewer episodes of urinary retention (5 versus 16) and surgery (2 versus 8). No adverse effects were reported.
  12. Yasumoto R, Kawanishi H, Tsujino T, Tsujita M, Nishisaka N, Horii A, Kishimoto T. Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia. Clin Ther. 1995;17(1):82-7. doi: 10.1016/0149-2918(95)80009-3.PubMedUsed to support: Uncontrolled study of 79 men aged 62 to 89 with prostate enlargement given 126 mg of cernitin extract three times a day for more than 12 weeks. Symptom scores fell, peak flow rose from 9.3 to 11 mL/s and residual urine fell; prostate volume did not change overall. No adverse reactions were observed. Without a control group, placebo effects cannot be excluded.
  13. Togo Y, Ichioka D, Miyazaki J, Maeda Y, Kameyama K, Yasuda M, Hiyama Y, Takahashi S, Nagae H, Hirota S, Yamamoto S, Japanese Research Group for Urinary Tract Infection (JRGU). Oral administration of cernitin pollen extract (Cernilton(®) ) for 30 days might be useful to avoid unnecessary biopsy in prostate biopsy candidates: A preliminary study. Int J Urol. 2018;25(5):479-485. doi: 10.1111/iju.13549.PubMedUsed to support: Uncontrolled study of 61 men with raised PSA awaiting prostate biopsy, given 2 tablets of cernitin pollen extract three times a day for 30 days. PSA fell by an average of 0.6 ng/mL (7.6%), with a different pattern in men with and without cancer on biopsy. Shows the extract can lower PSA readings; it does not show any effect on cancer.
  14. Kamijo T, Sato S, Kitamura T. Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats. Prostate. 2001;49(2):122-31. doi: 10.1002/pros.1126.PubMedUsed to support: Animal study in castrated older rats given estradiol to induce prostate inflammation. The full cernitin extract reduced damage to the gland lining (as did its GBX fraction) and limited stromal overgrowth (as did its T-60 fraction). Animal findings only.
  15. Dizeyi N, Mattisson IY, Ramnemark L, Grabe M, Abrahamsson PA. The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia: An in vitro study. Phytother Res. 2019;33(9):2457-2464. doi: 10.1002/ptr.6438.PubMedUsed to support: Cell study, with authors from the maker AB Cernelle, of cernitin T60 and GBX in prostate cell lines and human immune cells. The extract raised anti-inflammatory IL-10 but also pro-inflammatory IL-6 and IL-8, slowed prostate cell growth and lowered androgen receptor and PSA protein in stromal cells. Test-tube findings only.
  16. ClinicalTrials.gov Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) (NCT00919893) ClinicalTrials.gov registry. 2009;NCT00919893.SourceUsed to support: Registry record (not PubMed-indexed) for the 139-man placebo-controlled Cernilton trial. It lists the University of Giessen as sponsor with Strathmann (Germany) and Cernelle (Sweden) as collaborators, and describes each capsule as containing 23 mg dry pollen extract, 4 mg L-glutamate and 0.23 mg stigmasterol, taken as 2 capsules every 8 hours for 12 weeks.